RecruitingPhase 2NCT06188741
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Studying Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Karen Cole-Plourde, BA
- Intervention
- Selumetinib(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 1-8 years · All sexes
- Timeline
- 2025 – 2031
Study locations (13)
- Childrens of Alabama, Birmingham, Alabama, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Riley Hospital for Children/Indiana University, Indianapolis, Indiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- National Cancer Institute/ National Institutes of Health, Bethesda, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Texas, Southwestern, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06188741 on ClinicalTrials.govOther trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07407803Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGNANCT07233408Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health LiteracyMassachusetts General Hospital
- RECRUITINGNANCT06360406Real-World Treatment Study of Koselugo (Selumetinib)AstraZeneca
- RECRUITINGPHASE1, PHASE2NCT06159166Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).Johns Hopkins University
- RECRUITINGPHASE1NCT06104488A Study of Avutometinib for People With Solid Tumor CancersMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05521048Doxycycline in Cutaneous Schwannoma (NF2)Massachusetts Eye and Ear Infirmary
- ACTIVE NOT RECRUITINGNANCT03873610Resiliency Training in Adolescents With NF1 and NF2Massachusetts General Hospital
- RECRUITINGNCT04395495RASopathy BiorepositoryChildren's Hospital Medical Center, Cincinnati
See all trials for Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion →